Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Therapeutic immunology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 7584477
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Moving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma.

  2025cites this paper
• Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.

  2021cites this paper
• Development of oncolytic viruses for cancer therapy.

  2021cites this paper
• Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.

  2020cites this paper
• LegoBody: facile generation of bispecific and multi-specific antibodies

  2019cites this paper
• Antibody Structure and Function: The Basis for Engineering Therapeutics

  2019cites this paper
• David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments

  2019cites this paper
• mRNA as novel technology for passive immunotherapy

  2018cites this paper
• Utilizing Solid Phase Cloning , Surface Display And Epitope Information for Antibody Generation and Characterization

  2017cites this paper
• ANT-CD19 ANTIBODY CONSTRUCTS FOR THE TREATMENT OF B-CELL RELATED DSORDERS

  2017cites this paper
• Coomassie Blue-stained SDS / Polyacrylamide Gel of Purified bSCCD 19 xCD 3 plug

  2017cites this paper
• The making of bispecific antibodies

  2017cites this paper
• Bispecific antibodies in cancer immunotherapy

  2016cites this paper
• Bispecific antibodies.

  2015cites this paper
• Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

  2015cites this paper
• Bispecific antibodies ( bsAbs ) combine the functionality of two antibodies in one molecule . Two bsAb-drugs

  2015cites this paper
• Production of bispecific antibodies: diabodies and tandem scFv.

  2012cites this paper
• Bispecific Antibodies: Developments and Current Perspectives

  2011cites this paper
• Guidelines to cell engineering for monoclonal antibody production.

  2010cites this paper
• Antibody fragments

  2010cites this paper
• Improved immunotoxins with novel functional elements.

  2009cites this paper
• CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells

  2009cites this paper
• Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.

  2008cites this paper
• Literatur zum Artikel: Schwarz

  2007cites this paper
• Single-Chain Antibodies as New Antithrombotic Drugs

  2007cites this paper
• Construction and Purification of a Covalently Linked Divalent Tandem Single-Chain Fv Antibody Against Placental Alkaline Phosphatase

  2006cites this paper
• Breast carcinoma specific antibody selection combining phage display and immunomagnetic cell sorting.

  2006cites this paper
• Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker

  2006cites this paper
• Recombinant bispecific antibodies for cancer therapy

  2005cites this paper
• Antibodies and gene therapy: teaching old 'magic bullets' new tricks.

  2004cites this paper
• Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.

  2004cites this paper
• Recombinant bispecific antibodies for the targeting of adenoviruses to CEA‐expressing tumour cells: a comparative analysis of bacterially expressed single‐chain diabody and tandem scFv

  2004cites this paper
• Identification of potent human anti-IL-1RI antagonist antibodies.

  2004cites this paper
• The cloning, characterisation and engineering of an IGF-I-BINDING single chain Fv

  2004cites this paper
• The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

  2003cites this paper
• Bindungsdomäne-immunglobulin-fusionsproteine

  2002cites this paper
• Targeting Breast Cancer With Anti HER2/neu Diabodies

  2001cites this paper
• Expression of single-chain Fv-Fc fusions in Pichia pastoris.

  2001cites this paper
• Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.

  2001cites this paper
• Bispecific and bifunctional single chain recombinant antibodies.

  2001cites this paper
• New Recombinant Bi- and Trispecific Antibody Derivatives

  2001cites this paper
• Introduction: bispecific antibodies.

  2001cites this paper
• Expression of a bispecific dsFv-dsFv' antibody fragment in Escherichia coli.

  2000cites this paper
• Characterization of Human Inducible Costimulator Ligand Expression and Function1

  2000cites this paper
• T cell‐based immunotherapy for cancer: A virtual reality?

  1999cites this paper
• Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths.

  1999cites this paper
• Using Linker Peptides of Varying Lengths Generated from the Anti-CD 20 mAb 1 F 5 Characterization of scFv-Ig Constructs

  1999cites this paper
• Construction, Expression, and Characterization of Anticarcinoma sFv Fused to IL-2 or GM-CSF

  1999cites this paper
• Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants.

  1999cites this paper
• Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.

  1998cites this paper
• A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2.

  1998cites this paper
• Identification of novel diagnostic markers by differential display.

  1998cites this paper
• Antibody engineering.

  1997cites this paper
• Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen.

  1996cites this paper
• Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments.

  1996cites this paper
• PCR cloning and sequencing of a CD3-specific monoclonal antibody

  1996cites this paper
• Characterization of a CD43/Leukosialin-mediated Pathway for Inducing Apoptosis in Human T-Lymphoblastoid Cells*

  1996cites this paper
• A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL.

  1996cites this paper
• Computational biochemistry of antibodies and T-cell receptors.

  1996cites this paper
• Section Review Biologicals & Immunologicals The use of immunoconjugates in cancer therapy

  1996cites this paper
• Redirection of cellular cytotoxicity

  1995cites this paper
• Production of monoclonal antibodies in COS and CHO cells.

  1995cites this paper
• Alternative Triggering Molecules and Single Chain Bispecific Antibodies

  1995cites this paper
• Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.

  1995cites this paper
• Coengagement of CD2 with LFA‐1 or VLA‐4 by bispecific ligand fusion proteins primes T cells to respond more effectively to T cell receptor‐dependent signals

  1994cites this paper
• Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3×CD19 bispecific antibody to proliferate and become cytotoxic

  1994cites this paper
• Vecteurs d'expression codant pour des protéines de fusion bispécifiques et méthodes pour la production de ces protéines dans des cellules de mammifères

  1994cites this paper
• AD Award Number : DAMD 1798-1-8307 TITLE : Targeting Breast Cancer with Anti HER 2 / neu Diabodies

  year unknowncites this paper